Souhaitez-vous accéder aux communiqués récents ?

- IND Clearance of pheEDIT Study to Evaluate a One-Time Dose of Investigational HMI-103 Incorporating a Novel Nuclease-Free Gene Editing Approach - - Company Provides Update on Enrollment in...

- On Track to Report Initial Results from Phase 2 pheNIX Gene Therapy Trial for Adults with PKU in 2021- - Plans to Initiate First-Ever Gene Editing Trial for PKU with HMI-103 This Year - - Expects...

- ASGCT President and Entrepreneur Takes Leadership Role on SAB as Company Expects to Have Three Clinical Programs in 2021 - BEDFORD, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Homology Medicines,...

BEDFORD, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today participation in fireside chats at the...

- Data From New GTx-mAb Platform Demonstrated Proof of Principle for AAVHSCs to Deliver One-Time In Vivo Gene Therapy to Produce Antibodies in Humanized Murine Model - - Additional Data for HMI-203...

- On Track to Report Initial Phase 2 Data From pheNIX PKU Clinical Trial by Year End - - Announced New GTx-mAb Platform With Proof of Concept Data to Be Presented at Upcoming ASGCT Annual Meeting...

- Data Showed AAVHSCs Edited Human Retinal Cell Types Across Two Targets - - Demonstrated 11 AAVHSC Capsids Crossed Blood-Retinal and Blood-Brain Barriers in In Vivo Studies of Non-Human Primates...

- Proof of Concept Data for New GTx-mAb Platform to Be Featured at ASGCT Along With Presentations From Multiple Programs - - Company to Host Webcast on May 13 at 8:15 a.m. ET - BEDFORD, Mass., April...

- Data From Company’s PKU and Hunter Syndrome Gene Therapy Programs Featured in Presentations - BEDFORD, Mass., April 14, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a...

- Built Internal GMP Commercial Process and Manufacturing Platform and Scaled HEK293 Suspension System to 2,000L Under His Leadership - BEDFORD, Mass., April 12, 2021 (GLOBE NEWSWIRE) -- Homology...